Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Belfort – page 6

125 clinical trials in Belfort, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Belfort at a glance
125
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

125 trials in Belfort

Open in trial search

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nemtabrutinib
  • Sponsor:French Innovative Leukemia Organization

T-cell type acute leukaemia

Not yet recruiting

Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Centre Hospitalier De Versailles

Infertility male

Not yet recruiting

Study evaluating the effect of isotretinoin on sperm production in men with low sperm count

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Isotretinoin
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Cardiac failure+1

Not yet recruiting

A feasibility study of dapagliflozin for elderly patients hospitalized with chronic heart failure.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Dapagliflozin Propanediol Monohydrate
  • Sponsor:Centre Hospitalier Regional Universitaire

Study of pirtobrutinib combined with immuno-chemotherapy for previously untreated patients with symptomatic chronic lymphocytic leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:French Innovative Leukemia Organization

Non-small cell lung cancer

Not yet recruiting

Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Taiho Oncology Inc.

Plasma cell myeloma

Not yet recruiting

Study on Multiple Myeloma Treatment with Isatuximab, Lenalidomide, and Carfilzomib for Patients Under 66 Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Carfilzomib
  • Sponsor:Intergroupe Francophone Du Myelome

Pneumonia

Not yet recruiting

Study on CAL02 and Sodium Chloride for Patients with Severe Community-Acquired Bacterial Pneumonia

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cholesterol
  • Sponsor:Eagle Pharmaceuticals Inc.

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.

Neurodermatitis

Not recruiting

Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Belfort

What the registry says about research in the country

01 Respiratory and Circulatory Physiology

The clinical research activity in Belfort focuses on a small but clearly targeted set of studies within Phenomena and Processes, especially Circulatory and Respiratory Physiological Phenomena. These trials are examining how treatments may improve patient outcomes in serious lung and blood-circulation-related conditions.

  • Research in Chronic pulmonary aspergillosis is assessing better control of persistent fungal lung disease
  • Studies in Septic shock are exploring ways to support critically ill patients with severe circulatory failure
  • Clinical work is aimed at comparing treatment effectiveness and improving patient survival and recovery

This area brings together respiratory and intensive care research, with a focus on evaluating whether new or combined approaches can provide stronger clinical benefit than standard care alone.

02 Pulmonary Infection and Antifungal Care

One line of research is centered on Chronic pulmonary aspergillosis, a long-term fungal infection affecting the lungs. The studies are designed to test whether adding another therapy can improve both clinical response and imaging results in patients with limited immune suppression.

  • Focus on persistent fungal lung infection and treatment response
  • Evaluation of whether combination therapy offers added benefit over standard antifungal care
  • Interest in both symptom improvement and radiological outcomes

These trials help clarify how best to manage a difficult respiratory condition where long-term control is often a challenge.

03 Critical Care and Septic Shock Research

Another study area examines Septic shock in mechanically ventilated patients, with attention on treatments that may improve outcomes in severe, refractory cases. The goal is to see whether an added supportive therapy can reduce mortality alongside standard critical care.

  • Research on severe infection-related shock and organ support
  • Assessment of adjunctive treatment for patients not responding well to usual care
  • Outcome focus on short-term survival in intensive care settings

This work supports efforts to strengthen treatment strategies for one of the most urgent emergencies in intensive care medicine.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.